All In Biotech

Investigational drug · Phase 2

ST-1898

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Renal Cell Carcinoma, Differentiated Thyroid Carcinoma, Unresectable or Metastatic Melanoma.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

4

Any phase or sponsor naming "ST-1898"

First trial start

2023

Feb 7, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ST-1898", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Renal Cell Carcinoma
  • Differentiated Thyroid Carcinoma
  • Unresectable or Metastatic Melanoma

Approved drugs for the same conditions: Melanoma · Kidney cancer (renal cell carcinoma) · Oncology · Kidney and urology · Endocrinology and women's health

Largest trials

Live from ClinicalTrials.gov: studies naming "ST-1898" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Advanced Renal Cell Carcinoma

  • CasdatifanAB521Phase 33 trials

    Arcus Biosciences, Inc. · Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma (RCC)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.